Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

INTRODUCTION: The aim of this study was to assess the cost-utility of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm infants. METHODS: We used and adapted a pre-existent model in which two cohorts of patients received palivizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Chirico, Gaetano, Ravasio, Roberto, Sbarigia, Urbano
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687544/
https://www.ncbi.nlm.nih.gov/pubmed/19490659
http://dx.doi.org/10.1186/1824-7288-35-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687544/
https://www.ncbi.nlm.nih.gov/pubmed/19490659
http://dx.doi.org/10.1186/1824-7288-35-4

Ejemplares similares